SPR抗体;SPR Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Mouse liver tissue, human chromaffin cell tumor tissue, hepG2 cells, Primary antibody: P11529(SPR Antibody) at dilution 1/1500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P11529(SPR Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11529(SPR Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Surface plasmon resonance (SPR) antibodies are specialized tools used in SPR-based biosensing to detect and quantify molecular interactions in real-time. SPR technology measures changes in refractive index near a sensor surface, typically a gold-coated chip, when biomolecules bind to immobilized ligands. Antibodies, due to their high specificity, are often employed as capture agents in these systems. They are covalently attached to the sensor surface, enabling precise detection of target antigens in solutions without labeling.

SPR antibodies play a pivotal role in studying binding kinetics, providing data on association/dissociation rates (ka, kd) and equilibrium constants (KD). This label-free, real-time analysis is widely used in drug discovery, diagnostics, and protein interaction studies. For example, therapeutic antibody-antigen binding affinities are routinely characterized using SPR. However, challenges include minimizing non-specific binding and maintaining antibody orientation/activity during immobilization. Regenerating antibody-coated sensor surfaces for reuse also requires optimization to preserve functionality.

Commercial SPR platforms like Biacore heavily rely on high-quality antibodies for reproducible results. Recent advancements include nanobody-based SPR sensors for smaller footprints and multiplexed detection. These antibodies bridge biophysics with immunology, offering insights into molecular mechanisms while accelerating biomedical research and biotherapeutic development.